Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE
NCT05562518Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, randomised trial of estriol, dehydroepiandrosterone and hyaluronic acid in Vulvovaginal atrophy (VVA) (4 arms), sponsored by Ghent University Hospital. Primary endpoints: EuroQol-5 Dimension Questionnaire at 12 weeks, Functional Assessment of Cancer Therapy - Endocrine Symptoms at 12 weeks and 1 more. Started Mar 2022; status: completed.
02
Drugs
estrioldehydroepiandrosteronehyaluronic acid
03
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT05562518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562518.